These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 30332560)

  • 41. Toll-like receptors in systemic autoimmune disease.
    Marshak-Rothstein A
    Nat Rev Immunol; 2006 Nov; 6(11):823-35. PubMed ID: 17063184
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The critical role of Toll-like receptor signaling pathways in the induction and progression of autoimmune diseases.
    Li M; Zhou Y; Feng G; Su SB
    Curr Mol Med; 2009 Apr; 9(3):365-74. PubMed ID: 19355917
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A compass that points to lupus: genetic studies on type I interferon pathway.
    Kyogoku C; Tsuchiya N
    Genes Immun; 2007 Sep; 8(6):445-55. PubMed ID: 17581625
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pseudoviral immunity - a novel concept for lupus.
    Anders HJ
    Trends Mol Med; 2009 Dec; 15(12):553-61. PubMed ID: 19896418
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Toll-like receptors in systemic lupus erythematosus: potential targets for therapeutic intervention.
    Horton CG; Farris AD
    Curr Allergy Asthma Rep; 2012 Feb; 12(1):1-7. PubMed ID: 22086298
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The importance of the type I interferon system in autoimmunity.
    Rönnblom L
    Clin Exp Rheumatol; 2016; 34(4 Suppl 98):21-4. PubMed ID: 27586799
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Toll-Like Receptor Pathways in Autoimmune Diseases.
    Chen JQ; Szodoray P; Zeher M
    Clin Rev Allergy Immunol; 2016 Feb; 50(1):1-17. PubMed ID: 25687121
    [TBL] [Abstract][Full Text] [Related]  

  • 48. TBK1: A key regulator and potential treatment target for interferon positive Sjögren's syndrome, systemic lupus erythematosus and systemic sclerosis.
    Bodewes ILA; Huijser E; van Helden-Meeuwsen CG; Tas L; Huizinga R; Dalm VASH; van Hagen PM; Groot N; Kamphuis S; van Daele PLA; Versnel MA
    J Autoimmun; 2018 Jul; 91():97-102. PubMed ID: 29673738
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Type I interferon gene expression in antiphospholipid syndrome: Pathogenetic, clinical and therapeutic implications.
    Xourgia E; Tektonidou MG
    J Autoimmun; 2019 Nov; 104():102311. PubMed ID: 31378637
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice.
    Braun D; Geraldes P; Demengeot J
    J Autoimmun; 2003 Feb; 20(1):15-25. PubMed ID: 12604309
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Type III Interferons (Lambda Interferons) in Rheumatic Autoimmune Diseases.
    Mora-Arias T; Amezcua-Guerra LM
    Arch Immunol Ther Exp (Warsz); 2020 Jan; 68(1):1. PubMed ID: 31915933
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immune interferon in the circulation of patients with autoimmune disease.
    Hooks JJ; Moutsopoulos HM; Geis SA; Stahl NI; Decker JL; Notkins AL
    N Engl J Med; 1979 Jul; 301(1):5-8. PubMed ID: 449915
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular, metabolic and immune evidence suggest that systemic autoimmune disease is antigen-mediated.
    Benke PJ
    Med Hypotheses; 1996 Nov; 47(5):337-46. PubMed ID: 8951798
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Type I interferons in systemic autoimmunity.
    Sozzani S; Bosisio D; Scarsi M; Tincani A
    Autoimmunity; 2010 Apr; 43(3):196-203. PubMed ID: 20298124
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Standing on Shoulders: Interferon Research From Viral Interference to Lupus Pathogenesis and Treatment.
    Crow MK; Olferiev M; Kirou KA
    Arthritis Rheumatol; 2024 Jul; 76(7):1002-1012. PubMed ID: 38500017
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Toll-like receptors pathways implication in common autoimmune diseases and therapeutic perspectives.
    Alexoudi I; Kapsimali V; Vaiopoulos A; Kanakis M; Vaiopoulos G
    G Ital Dermatol Venereol; 2015 Apr; 150(2):255-60. PubMed ID: 25876147
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Regulation of T Cell Activation and Differentiation by Extracellular Vesicles and Their Pathogenic Role in Systemic Lupus Erythematosus and Multiple Sclerosis.
    Ulivieri C; Baldari CT
    Molecules; 2017 Feb; 22(2):. PubMed ID: 28157168
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The important roles of type I interferon and interferon-inducible genes in systemic lupus erythematosus.
    Luo S; Wang Y; Zhao M; Lu Q
    Int Immunopharmacol; 2016 Nov; 40():542-549. PubMed ID: 27769023
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Editorial: Type 1 interferon in pathologies, autoimmune diseases, and chronic viral infections: understanding the fascinating biologic role of type 1 interferons.
    Herbeuval JP
    Front Immunol; 2023; 14():1239086. PubMed ID: 37520531
    [No Abstract]   [Full Text] [Related]  

  • 60. The role of interferon in immediate hypersensitivity and autoimmune diseases.
    Hooks JJ; Moutsopoulos HM; Notkins AL
    Ann N Y Acad Sci; 1980; 350():21-32. PubMed ID: 6165276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.